Efficacy and safety of sofosbuvir/velpatasvir in the treatment of patients with genotype 3 and 6 chronic hepatitis C
YE Xiaoting1, XU Shuang1, Zhang Shengguo1, HONG Liang1, LU Mingqin2
1.Department of Infectious Disease, the Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200, China; 2.Department of Infectious Disease, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China
YE Xiaoting,XU Shuang,Zhang Shengguo, et al. Efficacy and safety of sofosbuvir/velpatasvir in the treatment of patients with genotype 3 and 6 chronic hepatitis C[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(8): 662-666.
Abstract：Objective: To analyze the efficacy and safety of sofosbuvir/velpatasvir in the treatment of patients with genotype 3 and 6 chronic hepatitis C. Methods: All 172 patients with genotype 3 and 6 chronic hepatitis C were selected from outpatient and inpatient departments of the Third Hospital of Wenzhou Medical
University from April 2020 to December 2021. Baseline characteristics of the patients were analyzed, and indicators before and after treatment were compared, including blood routine (white blood cell count, hemoglobin, platelets), liver and kidney function, HCV RNA, and abdominal imaging. The antiviral efficacy and safety of the patients were assessed by SVR12 (sustained viral response rate). Results: A total of 172 patients with confirmed chronic hepatitis C were enrolled, predominantly male (83%); genotype 3 accounted for 84% (46% of 3a and 38% of 3b) and genotype 6 accounted for 16%. There were 133 patients complicated with intravenous drug addiction. Out of 172 patients with confirmed chronic hepatitis C, 140 patients were treated with sofosbuvir/velpatasvir, with an SVR of 98.6% (138/140) at 12 weeks. ALT and AST were significantly reduced after treatment, and the APRI score improved after treatment compared with the pre-treatment, but there was no significant difference in blood routine (white blood cell count, hemoglobin, platelets) and creatinine of patients before and after treatment. No patients discontinued or died due to adverse drug reactions. Conclusion: Of patients with chronic viral hepatitis C genotype 3 and 6 in Wenzhou, Zhejiang Province, genotype 3 has a relatively high proportion, predominantly male and a high proportion of drug-users. Treatment with sofosbuvir/velpatasvir can achieve high virological response rate with good safety and tolerability.
